A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES
2017-001741-27TRATAMIENTO EN PRIMERA LÍNEA DE TUMORES MALIGNOS AVANZADOSFundación Jiménez DíazInvestigador: DOGER DE SPEVILLE BERNARD
